<DOC>
	<DOCNO>NCT01668511</DOCNO>
	<brief_summary>To assess safety , tolerability pharmacokinetics ABT-981 patient osteoarthritis knee .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacokinetics Multiple Subcutaneous Injections ABT-981 Patients With Osteoarthritis Knee</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled , multiple ascend dose study . Thirty-six patient osteoarthritis knee select participate . Patients randomize receive either ABT-981 placebo . ABT-981 placebo administer subcutaneous ( skin ) injection four dose group . Subjects administer subcutaneous injection ABT-981 8 week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Adult male female , 40 70 year age , inclusive . History symptomatic osteoarthritis ( OA ) knee joint least 3 month , typical Osteoarthritis ( OA ) symptoms Radiographic Osteoarthritis ( OA ) KellgrenLawrence ( KL ) grade 1 , 2 3 Patients assessment Osteoarthritis ( OA ) pain intensity study joint 40 80 0 100 mm VAS scale Other Osteoarthritis ( OA ) study joint , patient general good health Radiographic OA KellgrenLawrence grade 4 chronic opioid user due severe knee OA History allergic reaction significant sensitivity constituent study drug acetominophen history anaphylactic reaction agent Significant trauma surgery study joint within last year arthroscopy within 6 month , , schedule major surgery study joint Diagnosis rheumatoid arthritis , autoimmune disorder arthritis Osteoarthritis ( OA ) knee . Any uncontrolled medical illness include unstable treatment therapy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>